FM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis

NCT04710524 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Nonalcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis

Interventions

DRUG: Placebo
DRUG: FM101 150 mg BID
DRUG: FM101 300 mg BID

Sponsor

Future Medicine